This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Drug companies look to make Heritage-centric case bellwether in US generic drug pricing case

( March 1, 2021, 22:31 GMT | Official Statement) -- MLex Summary: Actavis, Amneal Pharmaceuticals, Glenmark Pharmaceuticals, and others told a US federal judge that the bellwether case in a wide-spanning litigation against the generic drug industry should be state attorneys general’s Heritage-centric action. They said the case involves a substantial (but more manageable) number or products, none of which are products included in the Teva action that recently lost bellwether status. See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections